BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vonsetamig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vonsetamig\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05092347-5819@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20271122
DTEND;VALUE=DATE:20271123
SUMMARY:Vonsetamig: Phase 1/2 readout est. (NCT05092347)
DESCRIPTION:Vonsetamig\, phase 1/2.\nStudy: A Study to Learn How Safe and T
 olerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD)
  Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukoc
 yte Antigen (HLA)\nEstimated primary completion: 22 November 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/vonsetamig#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05092347
URL:https://assetmemo.bio/drug/vonsetamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06975787-5819@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20290910
DTEND;VALUE=DATE:20290911
SUMMARY:Vonsetamig: Phase 1 readout est. (NCT06975787)
DESCRIPTION:Vonsetamig\, phase 1\, Systemic Lupus Erythematosus.\nStudy: Do
 se Escalation Study With Bispecific Antibodies in Adult Participants With 
 Lupus Nephritis\nEstimated primary completion: 10 September 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/vonsetamig#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06975787
URL:https://assetmemo.bio/drug/vonsetamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
